BIO 2022: ‘Limitless’ Innovation Is Harder With Limited Cash
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.